orthalign-1.jpg

OrthAlign, Inc. Appoints Eric B. Timko As New Chief Executive Officer and Chairman of the Board

Posted On March 2, 2017 By OrthoSpineNews In Recon /  

ALISO VIEJO, CA (PRWEB) MARCH 01, 2017

OrthAlign, Inc., a privately held U.S.-based medical device and technology company, announced today the appointment of Eric B. Timko as its new Chief Executive Officer and Chairman of the Board.

Mr. Timko is an accomplished medical device executive with more than 25 years of experience in the healthcare industry. He assumes his new leadership role at OrthAlign after serving on the company’s Board of Directors since July 2016. He previously served as President and Chief Executive Officer of Blue Belt Technologies, which under his leadership, was sold to Smith & Nephew in October 2015.

“I am very appreciative and excited to join OrthAlign as Chairman and CEO,” said Mr. Timko. “With close to 60,000 cases of consistent clinical outcomes completed, OrthAlign’s technology has made a positive impact on improving patient outcomes in joint replacement and will continue to do so for many years to come. Our immediate focus will be to expand our customer reach and our application pipeline so that more physicians and healthcare facilities can utilize our clinically beneficial and economically friendly portfolio of products.”

Prior to joining Blue Belt Technologies, Mr. Timko served as President and Chief Executive Officer of NeuroVasx, Inc., President of Carl Zeiss Surgical, Inc., and as Vice President of Siemens Medical Systems, Inc.

“As OrthAlign hits another inflection point in its successful history, the Board of Directors is delighted to have Eric take the reigns as Chairman and CEO of the company,” said Carter McNabb, OrthAlign Board Member and Managing Director of River Cities Capital Funds. “Eric’s prior leadership experience throughout his career is tailor made for the next stage of growth that lies ahead for OrthAlign. He is one of the medical technology industry’s most respected and innovative executives and we are confident that his leadership and vision will help fulfill the promise that our unique technology can bring to the changing orthopedic landscape.”

“The Board of Directors would also like to recognize outgoing OrthAlign CEO William Maya for his leadership over the past six years,” continues Mr. McNabb. “He has been instrumental in helping guide the organization through a critical growth period and effectively helped put OrthAlign technology on the global map. The OrthAlign family is extremely grateful for his service.”

About OrthAlign, Inc.

OrthAlign is a privately held medical device and technology company, committed to providing orthopedic surgeons with cutting edge, user-friendly, surgical navigation products for precise alignment and positioning. We believe that our technology will raise the standard of care in Joint Arthroplasty surgeries by making consistent and measurable results accessible and affordable to all surgeons, hospitals, and patients. Our strategy is to leverage this technology to provide simple and precision-driven solutions for a broad range of orthopedic procedures. For more information regarding OrthAlign, please visit http://www.orthalign.com.

“ORTHALIGN®, ORTHALIGN PLUS®, KNEEALIGN®, KNEEALIGN® 2, HIPALIGN®, and UNIALIGN™ are [registered] trademarks of OrthAlign, Inc.”

Read More

Alphatec’s Arsenal™ Deformity Adolescent Scoliosis (AIS) System Launched in Limited Markets in the U.S.

Posted On March 2, 2017 By OrthoSpineNews In Spine /  

CARLSBAD, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) — Alphatec Spine, Inc., (Nasdaq:ATEC), a global provider of spinal fusion technologies, announced today that the Company has launched its new Arsenal Deformity Adolescent Idiopathic Scoliosis (AIS) System and has successfully completed initial patient cases.  The limited release further expands the Company’s Arsenal Spinal Fixation System and targets the $650M U.S. deformity spine market.

The Arsenal AIS System gives surgeons a complete solution to address complex deformity pathologies, including unique uniplanar screws, which enable easier screw positioning and rod placement through a tulip that has 360 degrees of rotation, while restricting motion in the medial/lateral plane for derotation correction.  Additionally, the AIS system includes a wide variety of low-profile implants providing a better anatomical fit and increased ability to address patient pathologies, ergonomically designed instrumentation to improve surgical efficiency and comfort during complex surgeries, and proven biomechanical strength necessary to achieve a solid fusion.

Terry Rich, Alphatec Spine’s Chief Executive Officer commented, “With the launch of our differentiated AIS Deformity System we are able to compete directly with the market leaders in complex spine and it opens up a new segment for us in pediatric procedures.  This unique system extends our Arsenal platform and provides surgeons with easy-to-use, differentiated surgical tools for corrective maneuvers to better treat adolescent patients who are diagnosed with idiopathic scoliosis.  These successful initial patient cases demonstrate ATEC’s ongoing commitment to developing innovative solutions that are targeted at improving overall patient outcomes and surgeon experience.  The Arsenal AIS system gives us the opportunity to gain greater share in the deformity market and to benefit a vast number patients who are suffering today.”

Dr. Sheldon St. Clair, a pediatric orthopedic surgeon, and Dr. John Birknes, a pediatric neurosurgeon,  co-directors of the Spine Program at the Children’s Hospital of the King’s Daughters in Virginia, have partnered to treat pediatric spine deformities and performed the first deformity correction using the Arsenal AIS system. The patient was a skeletally immature 13-year-old with a hypokyphotic 49-degree thoracic scoliosis.  Drs. St. Clair and Birknes performed the surgery using the Arsenal uniplanar implants and cobalt-chromium alloy rods on a long construct across 9 levels from thoracic vertebrae T3 to T12.  Post-surgery, the patient’s thoracic curve has been eliminated, appropriate kyphosis has been restored, and the patient’s rib hump is no longer present.

“The entire Arsenal Deformity AIS set is fantastic, but the shining star is the ability to spin the uniplanar bodies independent of the screw shank, which allows surgeons to achieve optimal fixation and placement of the pedicle screws,” said Dr. St. Clair. “This unique feature enables the tulips to be placed at the perfect height and orientation to accept the rod and correct the deformity.  The slotted reduction towers are used both to reduce the rod into the tulips as well as to perform vertebral column manipulation to correct the spine in three planes of deformity. The reduction towers and transverse links are designed to be attached and removed with ease. The Arsenal AIS system provides strong, reliable implants, and two choices of cobalt chrome rods, enabling the surgeon to obtain excellent spinal deformity correction, which improves quality of life for the patient both now and for the future.”

About Alphatec Spine

Alphatec Spine, Inc., a wholly owned subsidiary of Alphatec Holdings, Inc. (Nasdaq:ATEC), is a medical device company that designs, develops, manufactures and markets spinal fusion technology products and solutions for the treatment of spinal disorders associated with disease and degeneration, congenital deformities and trauma. The Company’s mission is to improve lives by delivering advancements in spinal fusion technologies. The Company and its affiliates market products in the U.S. via a direct sales force and independent distributors.

Additional information can be found at www.alphatecspine.com.

Forward Looking Statements  

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management’s current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Alphatec Spine cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors.  Forward-looking statements include the Company’s ability to achieve profitable growth; the Company’s ability to achieve both domestic and international growth and future profitability.  The words “believe,” “will,” “should,” “expect,” “intend,” “estimate” and “anticipate,” variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement.  The important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to; the uncertainty of success in developing new products or products currently in Alphatec Spine’s pipeline within forecast timeframes, or at all, including without limitation the products discussed in this press release; the Company’s ability to compete directly with the market leaders in complex spine and open up a new segment for the Company in pediatric procedures; the Company’s ability to gain greater share in the deformity market and to benefit a vast number patients in such market; the acceptance of Alphatec Spine’s products by the surgeon community, including without limitation the products discussed in this press release;  and Alphatec Spine’s ability to develop and expand its U.S. revenues.  Please refer to the risks detailed from time to time in Alphatec Spine’s SEC reports, including its Annual Report Form 10-K, as well as other filings on Form 10-Q and periodic filings on Form 8-K.  Alphatec Spine disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

CONTACT: Investor/Media Contact:

Christine Zedelmayer
Investor Relations 
Alphatec Spine, Inc.
(760) 494-6610
czedelmayer@alphatecspine.com
Read More
Mazor-X.jpg

Mazor Robotics to Exhibit New Mazor X™ Surgical Assurance Platform at AANS/CNS Spine Summit Meeting

Posted On March 1, 2017 By OrthoSpineNews In Robotics, Spine, Top Stories /  

ORLANDO, FL–(Marketwired – March 01, 2017) – Mazor Robotics (TASE: MZOR) (NASDAQ: MZOR), a pioneer and leader in the field of surgical guidance systems, will demo the new Mazor X system at Spine Summit 2017, the Annual Meeting of the Section on Disorders of the Spine and Peripheral Nerves in Las Vegas, March 8-11.

Visit booth #1110 during exhibit hours or attend the following special presentations to learn more about Mazor X:

Lunch Seminar: Introducing Mazor X™: Mazor Robotics’ Next-Gen System
Moderator: Dr. Michael Steinmetz
Location: Valencia Ballroom
Date: Wednesday, March 8
Time: 12:30 – 1:30 pm

“What’s New” Session: Clinical Experience of Mazor Robotics Guidance Systems and O-Arm® Imaging in Degenerative and Deformity Cases
Faculty: Dr. Jeffrey L. Gum
Location: Demo Theater
Date: Friday, March 10
Time: 9:47 – 9:57 am

The Mazor X system consists of sophisticated 3D planning tools and an intra-op guidance system with a precision Surgical Arm indicated for implant and instrument positioning in spine surgery — the core of the Surgical Assurance Platform.

“Mazor’s core technology has been used in over 23,000 procedures. This unparalleled clinical and operating room experience has provided us with deep insight into what the surgeons want next for themselves and their patients,” said Mazor Robotics CEO Ori Hadomi. “So, we pushed the envelope, moving from a precise mechanical system, to a complete expandable platform that incorporates integrated analytics and state-of-the art guidance.”

“You plan your surgery and there is no heartache anymore,” said Orthopedic Surgeon Kornelis Poelstra, MD, PhD. “You know exactly where the screws are going to go.” Click here to watch full testimonial

Following Spine Summit, Mazor Robotics will also be exhibiting Mazor X at AAOS Annual Meeting in San Diego, March 14-18 (booth #2339).

About Mazor

Mazor Robotics (TASE: MZOR) (NASDAQ: MZOR) believes in healing through innovation by developing and introducing revolutionary technologies and products aimed at redefining the gold standard of quality care. Mazor Robotics Guidance Systems enable surgeons to conduct spine and brain procedures in an accurate and secure manner. For more information, please visit MazorRobotics.com.

Image Available: http://www.marketwire.com/library/MwGo/2017/2/28/11G131731/Images/mazor_bot-81c042b0c45195a0b5cfdad64568b31a.jpg

CONTACT INFORMATION

Read More
ZimmerBiometHQ_720.jpg

Zimmer Biomet Announces Quarterly Dividend for First Quarter of 2017

Posted On March 1, 2017 By OrthoSpineNews In Financial /  

WARSAW, Ind., March 1, 2017 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2017.

The cash dividend of $0.24 per share will be paid on or about April 28, 2017 to stockholders of record as of the close of business on March 31, 2017.  Future declarations of dividends are subject to approval of the Board of Directors and may be adjusted as business needs or market conditions change.

About Zimmer Biomet

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com, or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

 

SOURCE Zimmer Biomet Holdings, Inc.

Related Links

http://www.zimmer.com

Read More
DJO-Global.jpg

DJO Global Announces Appointment of Bryan McMillan as President, Regeneration

Posted On March 1, 2017 By OrthoSpineNews In Recon, Top Stories /  

March 1, 2017

SAN DIEGO–(BUSINESS WIRE)–

DJO Global, Inc., a leading global provider of medical technologies designed to get and keep people moving, today announced the appointment of Bryan McMillan as President Regeneration, effective March 1, 2017.

As President of DJO’s Regeneration business, Mr. McMillan will be responsible for both commercial growth strategies and corporate payor development and reimbursement initiatives. Mr. McMillan will report directly to DJO President and Chief Executive Officer, Brady Shirley.

“We are very excited to announce the appointment of Bryan McMillan as President of our Regeneration Business, Reimbursement, and Payor Development to provide effective, affordable solutions, giving patients and providers the attention they deserve to enhance the continuum of care,” said Brady Shirley, DJO President and Chief Executive Officer. “Throughout his career, Bryan has proven to be an agile leader with an extensive understanding of our specific segment and healthcare economics. We are confident that his ability to thrive in a variety of business environments to reach collective goals will serve DJO Global well in its commitment of being a world class organization.”

Mr. McMillan most recently served as the President of CoorsTek Medical, a position he was appointed to in March of 2014 after completing the successful integration of IMDS (Innovative Medical Device Systems) to the Coors family enterprise. In his role, Mr. McMillan was responsible for all functional areas and strategy for a division of the largest engineered ceramics company worldwide.

From 2010 to 2012, Mr. McMillan served in several key leadership positions at Orthofix International, N.V., culminating in his final role there as President for the Global Spine Business Unit. Prior to Orthofix, Mr. McMillan had a successful nine-year tenure at Stryker Corporation, where he held significant roles of increased responsibility, ultimately being promoted to the position of Vice President, Stryker Finance. In this capacity, Mr. McMillan built, developed and led a cross-divisional entity for Stryker to offer internal financing and strategic sales programs. During the “Great economic recession” and with capital equipment sales down, he led the division to record sales with nearly 30% growth in 2009. A large part of his unprecedented achievements can be attributed to Mr. McMillan’s demonstrated leadership skills, unique business acumen, and ability to transform multi-discipline business strategies into tangible outcomes.

Prior to entering the medical device industry, Mr. McMillan spent nearly ten years in investment management and banking with prestigious firms such as Rauscher Pierce, Everen Securities and CIBC Oppenheimer. Mr. McMillan received a Bachelor’s degree in Political Science and Business with honors from Arizona State University, and successfully completed the Harvard Executive Leadership program and Strategic Marketing Curriculum at the University of Texas, Austin.

About DJO Global

DJO Global is a leading global provider of medical technologies designed to get and keep people moving. The Company’s products address the continuum of patient care from injury prevention to rehabilitation after surgery, injury or from degenerative disease, enabling people to regain or maintain their natural motion. Its products are used by orthopedic specialists, spine surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers and other healthcare professionals. In addition, many of the Company’s medical devices and related accessories are used by athletes and patients for injury prevention and at-home physical therapy treatment. The Company’s product lines include rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management and physical therapy products. The Company’s surgical division offers a comprehensive suite of reconstructive joint products for the hip, knee and shoulder. DJO Global’s products are marketed under a portfolio of brands including Aircast®, Chattanooga, REGEN™, Compex®, DonJoy®, ProCare®, DJO® Surgical, Dr. Comfort® and Exos™. For additional information on the Company, please visit www.DJOglobal.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170301006385/en/

Read More
illus_11_.0-copie-750x0-c-default.jpg

Implanet Announces Grant of the French Patent for Jazz Lock®

Posted On March 1, 2017 By OrthoSpineNews In Regulatory, Spine /  

March 1, 2017

BORDEAUX, France & BOSTON–(BUSINESS WIRE)–

IMPLANET (IMPL.PA) (IMPZY) (Euronext: IMPL, FR0010458729, PEA-PME eligible; OTCQX: IMPZY), a medical technology company specializing in vertebral and knee-surgery implants, announces that the French patent office has granted a patent protecting the JAZZ Lock® implant in France.

A major component of an innovative range of band products for spine surgery, Jazz Lock® is an implant designed to treat degenerative spine disorders, whose global market potential is estimated at over $200 million.

An unrivaled implant, thanks to its locking system requiring no rod fixation, Jazz Lock® allows surgeons to shorten and simplify the surgical procedure by removing multiple steps and implants used in traditional system: locking screws and connecting rods.

Régis Le Couedic, Implanet’s Product Development & Manufacturing Director, says: “Obtaining this patent from the French patent office is the first step in fully protecting our Jazz Lock®, and more particularly, its locking mechanism that is the first of its kind in the market. The protection of this latter element is pivotal, insofar as the majority of our future developments will incorporate this technology. We continue to be extremely rigorous regarding the protection of our current and future innovations.”

Ludovic Lastennet, CEO of Implanet, adds: “We are continuing the strict execution of our development strategy, of which the comprehensive protection of our products is a major component. We have submitted the dossier to various global intellectual property authorities, notably the United States. Since its limited launch last autumn in the United States and Europe, Implanet has sold more than 300 Jazz Lock® implants to treat degenerative spine disorders. The clinical feedback from surgeons has been excellent, including important practical aspects such as ease of use and speed of implementation.”

Next financial press release: 2016 annual results, on March 28, 2017

IMPLANET will participate in the following events:

  • GES (“Groupement d’étude sur la Scoliose” scoliosis study group), Strasbourg, France, March 9 to 11, 2017
  • AAOS (American Academy of Orthopedic Surgery), San Diego CA, USA, March 15 to 17, 2017

About IMPLANET
Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 48 staff and recorded 2016 sales of €7.8 million. For further information, please visit www.implanet.com.
Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.
IMPLANET is listed on Compartment C of the Euronext™ regulated market in Paris.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170228007033/en/

Read More

Centric Medical™ Announces Initial Cases for Hammertoe Correction System

Posted On March 1, 2017 By OrthoSpineNews In Extremities /  

February 28, 2017

HUNTLEY, Ill.–(BUSINESS WIRE)–Centric Medical, a division of Life Spine, Inc., which focuses on developing surgical implants for the treatment of distal extremity pathology, announced today that the company has successfully completed initial cases with the Hammertoe Correction System. The innovative system offers a dual threaded design and is inserted between the proximal and middle phalanges so that the opposing threads fixate on the phalangeal canal of the toe and compress the joint.

“Centric Medical’s Hammertoe Correction System is the latest in the rapid evolution of permanent implants to improve the results of hammertoe surgery. This outpatient procedure is quick and the Hammertoe System provides excellent fixation and compression to permanently correct hammertoe deformities. Patients no longer need to have pins sticking out the ends of their toes, eliminating the requirement for follow-up surgery,” said Dr. David Friscia of Eisenhower Medical Center in Rancho Mirage, California.

The Hammertoe Correction System is scheduled for a limited release in Q2 of 2017. The initial case follows the news of FDA clearance of Centric Medical’s Metatarsal Hemi Implant. These systems are part of a growing portfolio which includes innovative osteobiologic products, as well as the groundbreaking TARSA-LINK™ Stand-Alone Wedge Fixation System, the market’s first stand-alone osteotomy wedge with built-in fixation. The system was released to the market in September 2016.

About Centric Medical

Centric Medical is dedicated to improving the quality of life for patients with distal extremity symptomatology, increasing procedural efficiency and efficacy through innovative design, uncompromising quality standards, and the most technologically advanced manufacturing platforms. Centric Medical, which is privately held, is based in Huntley, Illinois.

Contacts

Life Spine, Inc.
Mr. Mariusz Knap
Vice President of Marketing
847-884-6117
mknap@lifespine.com

Read More
10C33DD9F4730C52794705E4D8945A77.png

Cesca Therapeutics Strengthens Leadership Team and Board of Directors

Posted On March 1, 2017 By OrthoSpineNews In Biologics /  

RANCHO CORDOVA, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) — Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care autologous cell-based therapies, today announced that it has appointed Ms. Vivian Liu as its Chief Operating Officer and elected Dr. Russell Medford to its board of directors.

Ms. Vivian Liu, a member of Cesca’s board of directors since November 2016, has over 20 years of experience in finance, operations and M&A activities for private and public pharmaceutical companies. Prior to joining Cesca, Ms. Liu was the Managing Director of OxOnc Services Company, an oncology product development company.  From 1994-2010, she served in various executive roles at NexMed, Inc., which she co-founded and was later renamed Apricus Biosciences Inc. Ms. Liu obtained her MPA in International Finance from the University of Southern California and her B.A. from the University of California, Berkeley.

Dr. Russell Medford is a Managing Partner of the Salutramed Group, LLC and has extensive private and public company expertise. He is also currently the CEO of healthEgames, Inc., a digital healthcare company and serves as the Executive Chairman of ViaMune, Inc., which is developing new immuno-oncology therapies. Dr. Medford has served as the co-founder, President, CEO and Director of AtheroGenics, Inc. and was a founding board member of Inhibitex, Inc. serving on its board until its acquisition by Bristol-Myers-Squibb in 2012. He has led companies through multiple stages of therapeutic drug R&D developing novel, first-in-man clinical candidates for the treatment of cardiovascular disease, diabetes and arthritis. Dr. Medford obtained his M.D. and Ph.D. from the Albert Einstein College of Medicine.

“We are very pleased to have Vivian join the Cesca leadership team. Vivian has been a board member since November and with her diverse corporate finance and operations experience, the board is enthusiastic to have her take a much more involved role in the Company’s operations.” commented Dr. Xiaochun “Chris” Xu, Cesca’s Interim CEO. “Dr. Medford, who has a deep knowledge of drug development and clinical trials, will be of great value to the company as we continue to evaluate our clinical pipeline and prepare for our phase III trial in critical limb ischemia.  We look forward to working with both Vivian and Dr. Medford to help position Cesca as a leader in the broader healthcare industry.”

About Cesca Therapeutics Inc.
Cesca Therapeutics Inc. (www.cescatherapeutics.com) is engaged in the research, development, and commercialization of cellular therapies and delivery systems for use in regenerative medicine. The Company is a leader in the development and manufacture of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapeutics. These include:

  • The SurgWerks™ System (in development) – a proprietary system comprised of the SurgWerks Processing Platform, including devices and analytics, and indication-specific SurgWerks Procedure Kits for use in regenerative stem cell therapy at the point-of-care for vascular and orthopedic diseases.
  • The CellWerks™ System (in development) – a proprietary cell processing system with associated analytics for intra-laboratory preparation of adult stem cells from bone marrow or blood.
  • The AutoXpress® System (AXP®) – a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood.
  • The MarrowXpress™ System (MXP™) – a derivative product of the AXP and its accompanying sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow.
  • The BioArchive® System – an automated cryogenic device used by cord blood banks for the cryopreservation and storage of cord blood stem cell concentrate for future use.
  • Manual bag sets for use in the processing and cryogenic storage of cord blood.

Forward-Looking Statement
The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics’ forward-looking statements is set forth under the caption “Risk Factors” in Cesca Therapeutics annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

/EIN News/ —

Company Contact: Cesca Therapeutics Inc. 
                    ir@cescatherapeutics.com
                    
                    Investor Contact: The Ruth Group 
                    Lee Roth / Tram Bui 
                    646-536-7012 / 7035 
                    lroth@theruthgroup.com / tbui@theruthgroup.com

Primary Logo

Read More
invivo-therapeutics-7x4.jpg

InVivo Therapeutics to Present and Exhibit at Spine Summit 2017

Posted On February 28, 2017 By OrthoSpineNews In Neuro, Spine /  

CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced that two INSPIRE study Principal Investigators, Dom Coric, M.D. and Michael Fehlings, M.D., Ph.D., will be giving oral presentations at the Spine Summit 2017 to be held March 8-11, 2017 in Las Vegas, NV. Dr. Coric will present “INSPIRE Study Update on 10 Subjects Implanted with a Bioresorbable Polymer Scaffold Following Acute Complete Thoracic Spinal Cord Injury,” and Dr. Fehlings will present “Magnetic Resonance Imaging (MRI) Does Not Distinguish between Contusion and Compound Cord Lesions Following Severe (AIS A) Traumatic Acute Thoracic Cord Injury: Intraoperative Microsurgical Observations from the INSPIRE Trial” during the Peripheral Nerve, Basic Science Breakout session on Saturday, March 11.

Dr. Fehlings will also present during a What’s New Session on Friday, March 10. The session will include discussion of the Neuro-Spinal Scaffold™technology and INSPIRE study and will continue to raise awareness amongst leading spine neurosurgeons.

Mark Perrin, Chairman and CEO, said, “The Spine Summit affords us the opportunity to build mindshare within the most pertinent group of surgeons for the Neuro-Spinal Scaffold. This meeting has proven to be one of the most fruitful in terms of bringing on board new INSPIRE sites, and we look forward to having a significant presence at this meeting.”

The company will also have an exhibit booth to further foster relationships with the neurosurgical community. The meeting is the 33rd Annual Meeting of the AANS/CNS (American Associations of Neurological Surgeons / Congress of Neurological Surgeons) Joint Section on Disorders of the Spine and Peripheral Nerves and is being held in collaboration with the Korean Spinal Neurosurgery Society.

About the Neuro-Spinal Scaffold™ Implant

Following an acute spinal cord injury, the biodegradable Neuro-Spinal Scaffold is surgically implanted at the epicenter of the wound and is designed to act as a physical substrate for nerve sprouting. Appositional healing to spare spinal cord tissue, decreased post-traumatic cyst formation, and decreased spinal cord tissue pressure have been demonstrated in preclinical models of spinal cord contusion injury. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffoldreceived the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “believe,” “anticipate,” “intend,” “estimate,” “will,” “may,” “should,” “expect,” “designed to,” “potentially,” and similar expressions, and include statements regarding the addition of new sites. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the company’s ability to successfully open additional clinical sites for enrollment and to enroll additional patients; the ability to complete the INSPIRE study and submit an HDE; the company’s ability to receive regulatory approval for the Neuro-Spinal Scaffold; the company’s ability to commercialize its products; the company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the company’s products and technology in connection with the treatment of spinal cord injuries; the availability of substantial additional funding for the company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the company’s Annual Report on Form 10-K for the year ended December 31, 2015, and its other filings with the SEC, including the company’s Form 10-Qs and current reports on Form 8-K. The company does not undertake to update these forward-looking statements.

Contacts

InVivo Therapeutics
Brian Luque, 617-863-5535
Investor Relations
bluque@invivotherapeutics.com

Read More
MicroPort-Administration-Building.jpg

MicroPort Orthopedics Announces Results of Clinical Study, 98.8% Implant Survivorship of its Medial-Pivot Knee System at 17 Years

Posted On February 28, 2017 By OrthoSpineNews In Recon /  

February 28, 2017

ARLINGTON, Tenn.–(BUSINESS WIRE)–MicroPort Orthopedics Inc., a medical device company that develops and manufactures cutting edge joint replacement implants designed to help patients achieve full function faster, announced that The Knee has published a study evaluating long-term clinical and radiographic outcomes of the Medial-Pivot Knee System. The results demonstrate excellent clinical outcomes for both satisfaction (95%) and survivorship (98.8%) at 17 years with patients noting a great sense of stability and comfort during regular activities.1

It has been reported that approximately 20% of patients are not satisfied with the outcome of their total knee replacement as a result of residual pain and functional issues often attributed to implant design.2 MicroPort’s Medial-Pivot Knee System is uniquely designed to restore stability and normal knee kinematics to deliver reproducible outcomes that can improve function and drive patient satisfaction.

“I am in my third year of using the Evolution® Medial-Pivot Knee System and this publication validates the results that I have seen in my practice,” says David Backstein, MD, MEd, FRCSC, Head of Orthopaedic Surgery at Mount Sinai Hospital in Toronto, Ontario. “In my experience, the functional outcomes for patients treated with this system have certainly been superior than the systems I’ve used in the past and patients have fewer complaints. When I see them at six or eight weeks follow-up, they’re at a different stage of recovery than I was seeing previously with traditional implant designs. I’ve been exceptionally happy with the results and feel comfortable knowing I am implanting a prosthesis with 98.8% survivorship at 17 years.”

The paper, titled, A Long Term Clinical Outcome of the Medial Pivot Knee Arthroplasty System was authored by George A Macheras et al. from the “KAT” General Hospital, Athens, Greece. In the study, 325 patients with knee osteoarthritis underwent Total Knee Arthroplasty (TKA) using the Medial-Pivot prosthesis. All patients showed a statistically significant improvement in the Knee Society clinical rating system, Western Ontario and McMaster Universities Osteoarthritis Index, and Oxford knee score. The majority of patients (94%) were able to perform age-appropriate activities with average knee flexion of 120° and 98% of patients reported relief of pain to be excellent, very good or good. Additionally, survival analysis showed a cumulative success rate of 98.8% at 17 years.

About MicroPort Orthopedics
Established in January 2014, MicroPort Orthopedics Inc. is a multinational producer of orthopedic products and a proud member of the MicroPort Scientific Corporation family of companies. From its headquarters in Arlington, Tennessee, MicroPort Orthopedics develops, produces, and distributes innovative orthopedic reconstructive products. The company’s U.S.-based manufacturing and logistics capabilities deliver high quality hip and knee products to patients and their doctors in over 60 countries, including the U.S., EMEA, Japan, Latin America, and China markets. For more information about MicroPort Orthopedics, visit http://www.ortho.microport.com/.

About MicroPort
MicroPort Scientific Corporation is a leading medical device company focused on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 20 seconds in thousands of major hospitals around the world, MicroPort maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a patient-oriented global enterprise that improves and reshapes patient lives through application of innovative science and technology. For more information, please refer to: http://www.microport.com.

Forward-Looking Statements
Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words “believe,” “intend,” “expect,” “anticipate,” “project,” “estimate,” “predict,” “is confident,” “has confidence” and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort’s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

Sources:

1. George A. Macheras et al. “A long term clinical outcome of the Medial Pivot Knee Arthroplasty System.” The Knee Journal, Published: January 29, 2017.

2. Thambiah, Matthew Dhanaraj et al. “Patient Satisfaction after Total Knee Arthroplasty: An Asian Perspective.” Singapore Medical Journal 56.5 (2015): 259–263. PMC. Web. 22 Feb. 2017.

All rights reserved. 12294
Copyright © 2015 MicroPort Scientific Corporation

Contacts

LaVoie HealthScience
Sharon Correia, 617-412-8779
scorreia@lavoiehealthscience.com

Read More